OncoMatch/Clinical Trials/NCT07077512
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Is NCT07077512 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Autoleucel (Relmacabtagene Autoleucel) and Sintilimab (PD-1 inhibitor) for large b cell diffuse lymphoma.
Treatment: Autoleucel (Relmacabtagene Autoleucel) · Sintilimab (PD-1 inhibitor) — This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positivity (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Previous CAR-T cell therapy or other gene-modified T-cell treatments
Cannot have received: CD19-targeted therapy
Previous CD19-targeted therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous allogeneic hematopoietic stem cell transplantation
Lab requirements
Kidney function
adequate function of the kidneys
Liver function
adequate function of the liver
Cardiac function
adequate function of the heart
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify